Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) issued its earnings results on Monday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.16), Zacks reports.
Larimar Therapeutics Price Performance
NASDAQ:LRMR traded down $0.05 during trading hours on Friday, reaching $2.35. 986,346 shares of the stock were exchanged, compared to its average volume of 645,138. The stock has a market cap of $149.95 million, a PE ratio of -2.04 and a beta of 0.99. Larimar Therapeutics has a twelve month low of $2.19 and a twelve month high of $11.20. The firm has a 50 day moving average of $3.08 and a 200 day moving average of $5.10.
Wall Street Analyst Weigh In
LRMR has been the subject of several research analyst reports. HC Wainwright boosted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday. Robert W. Baird lowered their price target on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Tuesday. Guggenheim reiterated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday. Finally, Truist Financial assumed coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They set a "buy" rating and a $18.00 target price on the stock. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Larimar Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $20.22.
View Our Latest Stock Report on Larimar Therapeutics
About Larimar Therapeutics
(
Get Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Recommended Stories
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
